AMRN
Amarin Corporation plc
AMRN lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to grow.
AMRN Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Strong | |
| Unavailable |
AMRN's cash flow is currently strong, but its revenue and profitability are under pressure. There isn't enough data to rate its balance sheet.
AMRN PE Valuation
AMRN has no meaningful PE right now: it lost money over the past year.
AMRN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Decline | |
| Weakening | |
| Limited | |
| High |
Analysts expect AMRN's losses to grow, with revenue declining.
AMRN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.05 | +$3.20 |
| Q2 2026 | -$0.07 | +$4.36 |
| Q1 2026 | -$0.08 | +$4.32 |
| Q4 2025 | -$0.85 | +$3.15 |
| Q3 2025 | -$3.25 | -$1.25 |
| Q2 2025 | -$4.43 | -$2.63 |
| Q1 2025 | -$4.40 | -$1.80 |
| Q4 2024 | -$4.00 | -$1.00 |
AMRN is still losing money, but far less than before: $0.05 per share over the past year, against $5.36 at its worst in late 2022.
AMRN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $39.6M | -20% |
| Q2 2026 | $42.2M | -42% |
| Q1 2026 | $45.1M | +7.4% |
| Q4 2025 | $49.2M | -21% |
| Q3 2025 | $49.7M | +17% |
| Q2 2025 | $72.7M | +7.8% |
| Q1 2025 | $42M | -26% |
| Q4 2024 | $62.3M | -17% |
AMRN's revenue has slid since its 2020 peak: $40M last quarter, down 20% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -6% | +16 points |
| Q2 2026 | -28% | -6.5 points |
| Q1 2026 | -25% | +15 points |
| Q4 2025 | -13% | +72 points |
| Q3 2025 | -22% | +37 points |
| Q2 2025 | -22% | -21 points |
| Q1 2025 | -40% | -16 points |
| Q4 2024 | -84% | -78 points |
AMRN's operating margin was −6% last quarter, up 16 points from the same quarter a year ago.
AMRN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $9.2M | +$21.9M |
| Q2 2026 | $6.6M | -60% |
| Q1 2026 | $6.4M | +$18.8M |
| Q4 2025 | $15.3M | +$28.6M |
| Q3 2025 | -$12.7M | -$10.3M |
| Q2 2025 | $16.6M | +$19.4M |
| Q1 2025 | -$12.5M | +$142K |
| Q4 2024 | -$13.3M | -$12.7M |
AMRN's free cash flow has turned positive after two years mostly in the red: $37M over the past year.
AMRN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.7% | +11.4M shares |
| 1 year | +3% | +12.3M shares |
| 3 years | +1995% | +407M shares |
| 5 years | +2058% | +408M shares |
| Available history | +2398% | +411M shares |
AMRN has 428M diluted shares, up 3% from a year ago.
AMRN Net Leverage
AMRN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
AMRN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.1 | Neutral |
| Stochastic | 13.7 | Oversold |
AMRN's weekly RSI is 36 (neutral) and its Stochastic is 14 (oversold).
AMRN PE vs Healthcare Sector
AMRN has no meaningful PE right now: it lost money over the past year.
AMRN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $12.0 | 2.8% below |
| 20 week MA | $13.3 | 12% below |
| 50 week MA | $14.2 | 18% below |
| 100 week MA | $13.7 | 15% below |
| 200 week MA | $16.8 | 31% below |
AMRN is in a downtrend: it's below all five of its weekly moving averages, and 31% below its 200-week average.
AMRN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $431.0 | $100.2 | -77% |
| 2021 | $100.2 | $70.2 | -30% |
| 2022 | $70.2 | $25.0 | -64% |
| 2023 | $25.0 | $17.4 | -30% |
| 2024 | $17.4 | $8.96 | -49% |
| 2025 | $8.96 | $14.1 | +58% |
| 2026 YTD | $14.1 | $11.7 | -17% |
AMRN has finished lower in five of the last six years. It's down 17% so far in 2026.